



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Richard A. Rosenbloom
U.S. Serial No. 09/847,121
Filing Date: May 2, 2001
For: Compositions And Methods For The Treatment of Diabetic Neuropathy

:
:
: Group Art Unit:
: 1617
:
: Examiner:
: Mojedeh Bahar
:
: Attorney Docket No.:
: QUIG-1002US
:

#17
HKD
7-15-04

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R.
§1.97(b)(1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56 and 1.97(b)(1), Applicant brings to the Attention of the Examiner the documents listed on the attached Substitute Form PTO 1449 (in duplicate). As this Information Disclosure Statement is being filed Concurrently with an RCE application no fee is believed to be due. However, if any fee is due, the Commissioner is authorized to charge Deposit Account No. 50-0462. Moreover, please credit any overpayment to Deposit Account No. 50-0462.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8

I certify that this document, along with any document referred to as being attached, is being deposited with the U.S. Postal Service on 14 April 2004 as first class mail under 37 C.F.R. §1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Carla P. McDuffie
Name of person signing document


Carla P. McDuffie
Signature of person signing document

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Substitute PTO 1449 form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If the Examiner applies any of the documents as prior art against any claims in the application and Applicant determined that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Patent Office the relevant facts and law regarding the appropriate status of such documents. Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Respectfully submitted,

Date: April 14, 2004



Kevin J. Dunleavy
Registration No. 32,024

Customer No. 21302
KNOBLE YOSHIDA & DUNLEAVY, LLC
(Customer No. 21,302)
Eight Penn Center
Suite 1350
1628 John F. Kennedy Blvd.
Philadelphia, PA 19103
Telephone: (215) 599-0600
Facsimile: (215) 599-0601
E-Mail: kjdunleavy@patentwise.com




U.S. App. No.: 09/847,121
Filed: May 2, 2001
Group: 1617
Applicant: Rosenbloom
Docket No.: QUIG-1002US

Examiner Initial	Item No.	Document No.	Date	Name	Class	Subclass
	1US	4,617,187	October 14, 1986	Okuyama, et al		
	2US	5,571,441	November 5, 1996	Andon et al		
	3US	5,998,394	December 7, 1999	Voorhees et al		
	4US	5,804,168	September 8, 1998	Murad		
	5US	4,822,816	April 18, 1989	Markham		
	6US	5,070,085	Dec. 3, 1991	Markham		
	7US	6,296,861	Oct. 2, 2001	Perricone		
	8US	5,972,359	Oct. 26, 1999	Sine t al.		
	9US	5,776,460	Jul. 7, 1998	Kim et al.		
	10US	5,614,224	Mar. 25, 1997	Womack		
	11US	5,976,579	Nov. 2, 1999	McLean		
	12US	5,883,086	Mar. 16, 1999	Craft		
	13US	5,595,982	Jan. 21, 1997	Harless		
	14US	6,299,896	Oct. 9, 2001	Cooper et al.		
	15US	5,824,666	October 1, 1998	Deckner et al.		
	16US	5,922,335	July 1, 1999	Ptchelintasev, Dimitri		
	17US	4,250,097	February 1, 1981	Pfister, Jurg R.		
	18US	6,555,573	April 1, 2003	Rosenbloom, Richard Allen		
	19US	4,627,973	December 1, 1986	Moran et al		
	20US	6,054,128	April 1, 2000	Wakat, Diane		
	21US	6,051,602	April 1, 2000	Bissett, Donald Lynn		
	22US	5,686,082	November 1, 1997	N'Guyen, Quang-Lan		
	23US	5,648,083	July 1, 1997	Blieszner et al		
	24US	5,972,999	October 1, 1999	Murad, Howard		
	25US	5,709,868	January 1, 1998	Perricone, Nicholas V.		
	26US	5,872,140	February 1, 1999	Hesse et al.		
	27US	5,972,359	October 1, 1999	Sine et al.		
	28US	6,162,801	December 1, 2000	Kita		
	29US	6,048,886	April 1, 2000	Neigut		
	30US	5,876,737	March 1, 1999	Schonrock et al.		
	31US	5,952,391	September 1, 1999	Gers-Barlag et al.		
	32US	5,976,568	November 1, 1999	Riley		
	33US	5,770,260	July 1, 1998	Fukuyama et al		
	34US	6,592,896	July 15, 2003	Rosenbloom, Richard Allen		
	35US	6,596,313	July 22, 2003	Rosenbloom, Richard Allen		
	36US					
	37US					
	38US					
	39US					
	40US					
	41US					
	42US					
	43US					
	44US					
	45US					
	46US					
	47US					

EXAMINER:

DATE CONSIDERED:



FORM PTO-1449 Modified
Documents Cited by Applicant

U.S. App. No.: 09/847,121
Filed: May 2, 2001
Group: 1617
Applicant: Rosenbloom
Docket No.: QUIG-1002US

Examiner Initial	Item No.	Foreign Patent Document No.	Date	Country	Translation (Yes/No)
	1F	WO 97/18817	May-97	PCT	No
	2F	JP 07324037A	December 1, 1995	Japan	Yes
	3F				
	4F				
	5F				
	6F				
	7F				
	8F				
	9F				
	10F				
	11F				
	12F				
	13F				
	14F				
	15F				
	16F				
	17F				
	18F				
	19F				
	20F				
	21F				
	22F				
	23F				
	24F				
	25F				
	26F				
	27F				
	28F				
	29F				
	30F				
	31F				
	32F				
	33F				
	34F				
	35F				
	36F				
	37F				
	38F				
	39F				
	40F				
	41F				
	42F				
	43F				
	44F				
	45F				
	46F				
	47F				

EXAMINER:

DATE CONSIDERED:



FORM PTO-1449 Modified
List of Patents and Publications Cited by Applicant
Patent Trademark Office

Examiner Initial	Item No.	Other Documents (Including Author, Title, Date, Location and Pertinent Pages)
	1OD	Cunningham JJ, "The glucose/insulin system and vitamin C: implications in insulin-dependent diabetes mellitus", <u>J Am Coll Nutr</u> 1998 Apr;17(2):105-8 Abstract
	2OD	Crabbe MJ, et al., "Aldose reductase: a window to the treatment of diabetic complications?", <u>Prog Retin Eye Res</u> 1998 Jul;17(3):313-83 Abstract
	3OD	Fujita T, et al., "Inhibitory effects of perillosides A and C, and related monoterpene glucosides on aldose reductase and their structure-activity relationships", <u>Chem Pharm Bull</u> (Tokyo) 1995 Jun;43(6):920-6 Abstract
	4OD	Guillausseau PJ, Preventive treatment of diabetic microrangiopathy: blocking the pathogenic mechanisms", <u>Diabete Metab</u> , 1994;20(2 Pt 2):219-28 Abstract
	5OD	McAuliffe AV et al., "Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion" <u>Nephron</u> 1998 Nov;80(3):277-84 Abstract
	6OD	Eaton RP, et al., "A commentary on 10 years of aldose reductase inhibition for limited joint mobility in diabetes", <u>J Diabetes Complications</u> 1998 Jan-Feb;12(1):34-8 Abstract
	7OD	Rastelli G, et al. "Structural bases for the inhibition of aldose reductase by phenolic compounds", <u>Bioorg Med Chem</u> , 2000 May;8(5):1151-8 Abstract
	8OD	Costantino L, et al., "Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches" <u>Med Res Rev</u> , 1999 Jan;19(1):3-23 Abstract
	9OD	Hosotani H, et al., "Effects of topical aldose reductase inhibitor CT-112 on corneal sensitivity of diabetic rats" <u>Curr Eye Res</u> 1996 Oct;15(10):1005-7 Abstract
	10OD	Haraguchi H et al., "Inhibition of aldose reductase by dihydroflavonols in Engelhardtia chrysolepis and effects on other enzymes", <u>Experimentia</u> , 1996 June 15;52 (6) 564-7 Abstract
	11OD	Ohguro N, et al., "Topical Aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients" <u>Br J Ophthalmol</u> , 1995 Dec;79(12):1074-7 Abstract
	12OD	Benstead TJ, et al., "Nerve microvessel changes in diabetes are prevented by aldose reductase inhibition", <u>Can J Neurol Sci</u> 1995 Aug;22(3):192-7 Abstract
	13OD	Okada Y, et al., "Search for naturally occurring substances to prevent the complications of diabetes. II. Inhibitory effect of coumarin and flavonoid derivatives on bovine lens aldose reductase and rabbit platelet aggregation" <u>Chem Pharm Bull</u> (Tokyo) 1995 Aug;43(8):1385-7 Abstract
	14OD	Costantino L, et al., "1-Benzopyran-4-one antioxidants as aldose reductase inhibitors", <u>J Med Chem</u> 1999 Jun 3;42(11):1881-93 Abstract
	15OD	Nishimura-Yabe C, "Aldose reductase in the polyol pathway: a potential target for the therapeutic intervention of diabetic complications" <u>Nippon Yakurigaku Zasshi</u> 1998 Mar;111(3):137-45 Abstract
	16OD	Tomlinson DR, et al., "Aldose reductase inhibitors and their potential for the treatment of diabetic complications" <u>Trends Pharmacol Sci</u> 1994 Aug;15(8):293-7 Abstract
	17OD	Airey M, et al., "Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy", <u>Cochrane Database Syst Rev</u> 2000;(2):CD002182 Abstract
	18OD	Maxwell SR, et al., "Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus", <u>Eur J Clin Invest</u> 1997 Jun;27(6):484-90 Abstract
	19OD	Himmerich S., et al., "Effect of Vitamins E and C on Nitric Oxide Production in Oxidized Low Density Lipoprotein Treated Human Aortic Endothelial Cells", <u>Academic Press</u> ; 2000, internet download at http://www.academicpress.com/www/journal/niox/9204.html
	20OD	Asahi K, et al., "Nitric Oxide Inhibits the Formation of Advanced Glycation End Products", <u>Kidney Int</u> 2000 Oct;58(4):1780-7

EXAMINER:


DATE CONSIDERED:



Examiner Initial	Item No.	Other Documents (Including Author, Title, Date, Location and Pertinent Pages)
	21OD	McCarty MF, "Nitric oxide deficiency, leukocyte activation and resultant ischemia are crucial to the pathogenesis of diabetic retinopathy/neuropathy - preventive potential of antioxidants, essential fatty acids, chromium, ginkgolides, and pentoxifylline" <u>Med Hypotheses</u> 1998 May;50(5):435-49 Abstract
	22OD	Boulton AJ, et al., "Guidelines for diagnosis and outpatient management of diabetic peripheral neuropathy", <u>Diabetes Metab</u> 1998 Nov;24 Suppl 3:55-65 Abstract
	23OD	Tutuncu NB et al., "Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study", <u>Diabetes Care</u> , 1998 Nov;21(11):1915-8 Abstract
	24OD	van Dam PS, et al., "Diabetic peripheral neuropathy: international guidelines for prevention, diagnosis, and treatment (comment)", <u>Ned Tijdschr Geneeskde</u> 2000 Feb 26;144(9):418-21 Abstract
	25OD	Zangaro GA et al., "Diabetic neuropathy: pathophysiology and prevention of foot ulcers" <u>Clin Nurse Spec</u> 1999 Mar;13(2):57-65; quiz 66-8. Abstract
	26OD	Boulton AJ, et al., "Diabetic Neuropathy", <u>Med Clin North Am</u> , 1998 Jul;82(4):909-29 Abstract
	27OD	Feldman EL, et al., "Pathogenesis of diabetic neuropathy" <u>Clin Neurosci</u> , 1997;4(6):365-70 Abstract
	28OD	Qian M, et al., "Glycochelates and the etiology of diabetic peripheral neuropathy" <u>Free Radic Biol Med</u> 2000 Feb 15;28(4):652-6 Abstract
	29OD	Galer BS, et al., "Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life", <u>Diabetes Res Clin Pract</u> 2000 Feb;47(2):123-8 Abstract
	30OD	Kaneto H, et al., "Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity" <u>Diabetes</u> 1999 Dec;48(12):2398-406 Abstract
	31OD	Simon-Schnass I., et al. "Nutrient Intake of 130 Type II Diabetics", Nutrisan®, Privat-institut für Ernährungswissenschaft Dr. Irene Simon-Schnass, Unterfeldstrasse 5a, D-82377 Penzberg
	32OD	DiSilvestro R., "Zinc Deficiency-Diabetes Link Explored", internet download May 31, 2000 at http://www1.rf.ohio-state.edu/pubrpt/mh/zinc.htm
	33OD	Chusid, R., "Vitamins and Diabetes", internet download Sept. 25, 2000 at http://ourworld.compuserve.com/homepages/rchusid.vdm.htm
	34OD	"Alternative Therapies for Diabetes" by National Diabetes Information Clearinghouse, May 1999.
	35OD	Salonen JT et al., "Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year follow up study in men" <u>BMJ</u> 1995 Oct 28;311(7013):1124-7 Abstract
	36OD	Fox GN et al., "Chromium picolinate supplementation for diabetes mellitus" <u>Fam Pract</u> 1998 Jan;46(1):83-6 Abstract
	37OD	Nutrition Dynamics Inc., "Glyco Control."
	38OD	Diabetic Polyneuropathy, "Pathophysiology", Volume 1, 1999, Medscape, Inc.
	39OD	Diabetic Polyneuropathy, "Future Therapies", Vol. 1, 1999, Medscape, Inc.
	40OD	Diabetic Polyneuropathy, "Neurologic Examination", Volume 1, 1999, Medscape, Inc.
	41OD	Diabetic Polyneuropathy, "Symptom History", Vol. 1, 1999, Medscape, Inc.
	42OD	Van Acker et al., "Structural Aspects of Antioxidant Activity of Flavonoids", <u>Free Radic Biol Med</u> 1996;20(3):331-42 Abstract

EXAMINER:

DATE CONSIDERED:



FORM PTO-1449 Modified
List of Patents and Publications Cited by Applicant
U.S. Patent Trademark Office

Examiner Initial	Item No.	Other Documents (Including Author, Title, Date, Location and Pertinent Pages)
	43OD	Tiukavkima, et al., "Dihydroquercetin - a new antioxidant and biologically active food additive", <u>Vopr Pitan</u> 1997;(6):12-5 Abstract
	44OD	Plumb, et al., "Antioxidant properties of flavonal glycosides from tea", <u>Redox Rep</u> 1999;4(1-2):13-6 Abstract
	45OD	Duke, et al., "Biological Activities of CURCUMINOIDS", <u>Phytochemical and Ethnobotanical Database</u> .
	46OD	Robak, et al., "Bioactivity of flavonoids", <u>Pol J Pharmacol</u> 1996 Nov-Dec;48(6):555-64 Abstract
	47OD	Bursel, et al., "Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications?", <u>Diabetes Res Clin Pract</u> 1999 Sep; 45(2-3):169-82 Abstract
	48OD	Freedman, et al., "Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release", <u>Circulation</u> 2001 Jun 12;103(23):2792-8 Abstract
	49OD	Lin, et al., "Recent studies on the biofunctions and biotransformations of curcumin", <u>Biofactors</u> 2000;13(1-4):153-8 Abstract
	50OD	Duarte, et al., "Vasodilator effects of quercetin in isolated rat vascular smooth muscle", <u>Eur J Pharmacol</u> 1993 Aug 239:1-7 Abstract
	51OD	Giugliano, et al., "Oxidative stress and diabetic vascular complications", <u>Diabetes Care</u> 1996 Mar;19(3):257-67 Abstract
	52OD	Fukuoka, M. et al., "Novel pharmacological activity of a vitamin (novel pharmacological action of vitamin D)", <u>Medscape Medline abstract</u> , <u>Nippon Yakurigaku Zasshi</u> October 1997, 110 Suppl. 1:39P-43P Abstract
	53OD	Riaz S. et al., "A vitamin D3 derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats", <u>Medscape Medline Abstract</u> , <u>Diabetologia</u> November 1999, 42(11): 1308-1313. Abstract
	54OD	Okada, Y, et al (cont) <u>Chem. Pharm Bull (Tokyo)</u> Aug. 1995, 43(8): 1385-1387. Abstract
	55OD	Sports Medicine Articles" (online), 01 September 2000 (retrieved on 2002-01-10) Retrieved from the Internet http://www.rehabnet.com/Sports/Actinic%20Dermatitis.htm , p. 1-2
	56OD	
	57OD	
	58OD	
	59OD	
	60OD	
	61OD	
	62OD	
	63OD	

EXAMINER:

DATE CONSIDERED: